Retatrutide, developed by Soma Pharmaceuticals , is gaining significant attention as a innovative therapy for obesity management . This unique medication integrates the properties of a GLP-1 receptor agonist and a GIP receptor stimulant, aiming to effectively promote weight loss but also improve